A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Multiple Myeloma (MM) is a hematologic malignancy.
• Bortezomib (Bor)-based therapies are standard treatments.
• Optimizing treatment regimens for efficacy and safety is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of a dose-increased weekly Bortezomib (Bor)-based combination therapy.
• To compare this modified regimen against conventional Bortezomib therapy in MM patients.

Main Methods:

• A monocentric, prospective, non-randomized, phase IV, non-inferiority trial.
• Thirty MM patients received modified Bor therapy (1.6 mg/m2 weekly).
• Thirty-four MM patients received conventional Bor therapy (1.3 mg/m2 bi-weekly) as control.

Main Results:

• Overall response rates (ORR) were 76.6% (modified) vs 82.3% (control).
• Median progression-free survival (PFS) was 16 months (modified) vs 12 months (control).
• Peripheral neuropathy (PN) incidence was significantly lower in the modified group (10% vs 32.4%).

Conclusions:

• Dose-increased weekly Bortezomib (Bor) is non-inferior to conventional regimens for MM response and survival.
• The modified regimen offers a significant reduction in peripheral neuropathy (PN).
• This approach represents a potentially safer treatment option for multiple myeloma.